Ulcer News and Research

RSS

Twenty-five million Americans suffer from ulcers. An ulcer is a sore or hole in the lining of the stomach or duodenum (the first part of the small intestine). People of any age can get an ulcer and women are affected just as often as men.

Helicobacter pylori (H. pylori) is a bacterium that lives on the lining of the stomach. Although we used to think that spicy food, acid, and stress were the major causes of ulcers, we now know that nine out of ten ulcers are caused by H. pylori. Medicines that reduce stomach acid may make you feel better, but your ulcer may come back. Here's the good news: Since most ulcers are caused by this bacterial infection, they can be cured with the right antibiotics.

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Duchesnay USA today announced that Diclegis (doxylamine succinate 10mg, pyridoxine hydrochloride 10mg) delayed-release tablets for the treatment of nausea and vomiting of pregnancy, more commonly known as morning sickness, is now available for coverage under the state and federal Medicaid program effective July 1st, 2013.

9 Jul 2013

Endoscopic imaging: an interview with Len Farris, Vice President of Marketing, Americas, PENTAX Medical

The impact of endoscopic imaging on patient care has been enormous since the first fiber optic systems were introduced more than 50 years ago. Today, high resolution and high definition systems are used to provide clinicians and patients unprecedented images from inside the body.

From PENTAX Medical Company 3 Jul 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

Hebrew University student develops drug formulations to treat illnesses through skin applications

New, more efficient drug formulations designed to treat illnesses through skin applications -- thus avoiding serious side effects associated with oral drug-taking -- have been developed by a student at the Hebrew University of Jerusalem.

12 Jun 2013

Renowned pathologist warns about possible consequences of silicone use in breast reconstruction

The public and the press were electrified in early May when superstar actress and filmmaker Angelina Jolie announced in a New York Times opinion piece that she had received a double mastectomy and follow-up breast reconstruction. Renowned pathologist Rahim Karjoo M.D ., F.C.A.P., F.A.S.C.P., is an expert in the diagnosis and treatment of Morgellons disease, an illness that is little known or acknowledged in the mainstream medical community.

1 Jun 2013

Columbia University, Chinese Center for Disease Control to open joint pathogen discovery lab in Beijing

The Center for Infection and Immunity at Columbia University's Mailman School of Public Health and the National Institute for Viral Disease Control and Prevention within the Chinese Center for Disease Control and Prevention will open a Joint Research Laboratory for Pathogen Discovery to conduct surveillance, identify new infectious microbes, establish novel platforms for diagnostics, and develop drugs and vaccines to treat diseases in humans and animals.

29 May 2013

New data highlights urgent crisis posed on US healthcare system by DFUs and VLUs

Organogenesis Inc., a commercial leader in the field of regenerative medicine, presented new data generated in collaboration with a team of expert economists from Analysis Group (a leading health economics consultancy) demonstrating the significant healthcare resource and economic burden that diabetic foot ulcers and venous leg ulcers place upon the US healthcare system.

23 May 2013

Novel medicine for chronic wound treatment

Every 20 seconds, a limb is lost as a consequence of diabetic foot ulcer that does not heal. To date, medical solutions that can change this situation are very limited.

20 May 2013

Genetic loci associated with H pylori bacteria are linked to stomach cancer

Two genome-wide association studies and a subsequent meta-analysis have found that certain genetic variations are associated with susceptibility to Helicobacter pylori, a bacteria that is a major cause of gastritis and stomach ulcers and is linked to stomach cancer, findings that may help explain some of the observed variation in individual risk for H pylori infection, according to a study in the May 8 issue of JAMA.

8 May 2013

Scientists discover novel drug molecule that reduces swelling, inflammation in arthritic joints

A gas associated with the smell of rotten eggs has proven to effectively reduce joint swelling, in research which could lead to advances in the treatment of arthritis.

30 Apr 2013

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.

26 Apr 2013

Pediatric nurse scientist awarded AACN Impact Research Grant

The American Association of Critical-Care Nurses recently awarded a $50,000 AACN Impact Research Grant to Martha A.Q. Curley, RN, PhD, FAAN, a leading clinical scientist in pediatric critical care nursing.

24 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

Ulcer News and Research

Diclegis delayed-release tablets for NVP treatment now eligible for Medicaid coverage

Endoscopic imaging: an interview with Len Farris, Vice President of Marketing, Americas, PENTAX Medical

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

Hebrew University student develops drug formulations to treat illnesses through skin applications

Renowned pathologist warns about possible consequences of silicone use in breast reconstruction

Columbia University, Chinese Center for Disease Control to open joint pathogen discovery lab in Beijing

New data highlights urgent crisis posed on US healthcare system by DFUs and VLUs

Novel medicine for chronic wound treatment

Genetic loci associated with H pylori bacteria are linked to stomach cancer

Scientists discover novel drug molecule that reduces swelling, inflammation in arthritic joints

Derma Sciences initiates patient screening in DSC127 pivotal program for treatment of diabetic foot ulcers

Pediatric nurse scientist awarded AACN Impact Research Grant

BD receives FDA approval for second prefilled injectable drug

AACN awards Impact Research Grant to Detroit palliative care expert

High dietary salt combined with ulcer infection greatly increases risk of gastric cancer

Fruit fly study offers clues to wound healing

AAWC translates patient education brochure on pressure ulcers into Spanish

Mycolactone activation of N-WASP boosts Buruli ulcer formation

Weekend reading: Humanizing hospitals, splurge of health data and huge sodas

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News